Evidence map›Paper›PMID 41383117›Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

NAD

Jia Song, Yuting Sun, Nan Zang, Xue Liu, Jiamu Chen, Kewei Wang, Longqing Xia, Jun Chen, Ruxing Zhao, Fuqiang Liu and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. A sustained NADBioactive materials · 2026
    Article
  2. Article
  3. Review
  4. NADJournal of cachexia, sarcopenia and muscle · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jia SongDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Yuting SunDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Nan ZangDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Xue LiuDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Jiamu ChenDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Kewei WangDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Longqing XiaDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Jun ChenDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Ruxing ZhaoDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Fuqiang LiuDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Xinguo HouDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Li ChenDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Jun ChengDepartment of Clinical Laboratory, Shandong Engineering & Technology Research Center for Tumor Marker Detection, The Second Qilu Hospital of Shandong University, Jinan, Shandong, China.
Wenjian ZhangDepartment of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, Shandong, China.

Funding

Major Basic Research Project of the Shandong Provincial Natural Science Foundation ZR2022ZD15National Natural Science Foundation of China 82203191National Natural Science Foundation of China 82501893Natural Science Foundation of Shandong Province ZR2024QH510Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0507700Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0507702Second Qilu Hospital of Shandong University 2023JX27
6 · The paper itself

Abstract

backgroundSarcopenia contributes to all-cause mortality in the elderly; however, there is no specific treatment. Mesenchymal stromal cells (MSCs) ameliorate age-related muscle loss and dysfunction and are potential therapeutic candidates for sarcopenia. However, their activity is easily affected by the surrounding environment and they are prone to replicative senescence during in vitro culture. Therefore, a drug that delays aging and enhances its function is required. Here, we investigated whether nicotinamide adenine dinucleotide (NAD

methodsThe administration of D-gal to mice induces a range of age-associated characteristics and is commonly used in research on age-related muscle atrophy. Therefore, in this study, C57BL/6 J mice and C2C12-differentiated myotubes exposed to D-gal were used to explore the effects of MSCs/NAD

resultsMSCs increased grip strength (p = 0.0005), running endurance (p = 0.0006) and muscle mass (p = 0.0165 for tibialis anterior [TA] muscle, p = 0.0049 for soleus [SO] muscle) in D-gal-treated mice, with elevated muscle fibre CSA (p < 0.0001) and reduced Atrogin 1 (p = 0.0242) and MuRF1 expression (p = 0.0009). NAD

conclusionsNAD

Indexed as

CytokinesMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMitochondriaMuscular AtrophyNADNicotinamide PhosphoribosyltransferaseSirtuin 1AnimalsDisease Models, AnimalGalactoseMaleMiceMice, Inbred C57BLMuscle, SkeletalSarcopeniaCytokinesGalactoseNADNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, mouseSirt1 protein, mouseSirtuin 1mitochondrial functionmuscle atrophyNAD+‐MSCsNAMPTSIRT1/PGC‐1α

Identifiers

PMID41383117
PMCPMC12699140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.